Scientists test new drug duo against tough thyroid cancers
NCT ID NCT01947023
Summary
This early-stage study is testing the safety and best dose of a two-drug combination (dabrafenib and lapatinib) for adults with advanced thyroid cancer that has a specific genetic change (BRAF mutation) and has stopped responding to standard treatments. The main goal is to see how much of the drug lapatinib can be safely given alongside dabrafenib. Researchers will also check if the treatment shows any signs of shrinking tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC THYROID GLAND CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.